TY - JOUR
T1 - Contentious Issues in Gout Management
T2 - The Story so Far
AU - Talaat, Mohamed
AU - Park, Kyle
AU - Schlesinger, Naomi
N1 - Funding Information: NS: Research grant funding from AMGEN and consulting fees Horizon Therapeutics, IFM Therapeutics, Johnson and Johnson . Publisher Copyright: © 2021 Talaat et al.
PY - 2021
Y1 - 2021
N2 - Gout is the most common inflammatory arthritis worldwide. Although gout has been known for antiquity, many challenges still exist in gout management. It is vital to view gout as a chronic disease and not just treat the acute flare. There is a perception of gout as an acute disease requiring treatment only for acute flares. However, to combat the disease, chronic urate-lowering therapy, reducing the serum urate levels to below the saturation threshold of 6.8 mg/dL, and chronic anti-inflammatory prophylaxis, especially during urate-lowering therapy initiation, are needed. In this manuscript, we discuss some of the contentious issues in gout management. These include the timing of urate-lowering therapy initiation, which urate-lowering therapy to chose, should comorbidities influence our treatment, using genetic determinants, and patient perspectives to drive treatment and differences between gout treatment the American College of Physicians and Rheumatology guidelines for gout management: driving care.
AB - Gout is the most common inflammatory arthritis worldwide. Although gout has been known for antiquity, many challenges still exist in gout management. It is vital to view gout as a chronic disease and not just treat the acute flare. There is a perception of gout as an acute disease requiring treatment only for acute flares. However, to combat the disease, chronic urate-lowering therapy, reducing the serum urate levels to below the saturation threshold of 6.8 mg/dL, and chronic anti-inflammatory prophylaxis, especially during urate-lowering therapy initiation, are needed. In this manuscript, we discuss some of the contentious issues in gout management. These include the timing of urate-lowering therapy initiation, which urate-lowering therapy to chose, should comorbidities influence our treatment, using genetic determinants, and patient perspectives to drive treatment and differences between gout treatment the American College of Physicians and Rheumatology guidelines for gout management: driving care.
KW - controversies
KW - gout
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85114175720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114175720&partnerID=8YFLogxK
U2 - https://doi.org/10.2147/OARRR.S282631
DO - https://doi.org/10.2147/OARRR.S282631
M3 - Review article
VL - 13
SP - 111
EP - 122
JO - Open Access Rheumatology: Research and Reviews
JF - Open Access Rheumatology: Research and Reviews
SN - 1179-156X
ER -